Gossamer Bio (GOSS) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company focus and pipeline overview

• Focused on seralutinib, a multikinase inhibitor for pulmonary arterial hypertension (PAH), currently in a global phase III trial across 174 sites in 31 countries, with data expected in Q4 next year.

• Plans to initiate a second phase III trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) next year, targeting a larger and sicker patient population.

• Commercial launch with partner Chiesi is targeted for 2027, with a second approval in PH-ILD anticipated soon after.

Clinical development and trial results

• Phase II TORREY trial showed a 14% reduction in pulmonary vascular resistance (PVR), with further reductions up to 25% in long-term open-label extension, and a favorable safety profile dominated by headache and cough.

• Efficacy in less sick patients was demonstrated, with stronger results in sicker subgroups, guiding phase III enrollment to focus on higher-risk patients using the REVEAL Lite composite.

• Durable and deep impact observed in long-term patients, with ongoing data collection through six-minute walk tests and continued updates at medical conferences.

Competitive landscape and differentiation

• Seralutinib was designed for inhaled delivery to minimize systemic side effects seen with oral imatinib; competitor Aerovate's inhaled imatinib program failed, likely due to underdosing and lack of inhalation-specific design.

• Real-world safety concerns with Winrevair (sotatercept) have benefited seralutinib's trial enrollment, as physicians weigh safety and monitoring burdens.

• Outside the US and Germany, commercial competition is limited, with most trial enrollment expected from Europe.